- Home
- DOMO vs ESPR Comparison
DOMO vs ESPR Comparison
Compare DOMO & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOMO
- ESPR
- Stock Information
- Founded
- DOMO 2010
- ESPR 2008
- Country
- DOMO United States
- ESPR United States
- Employees
- DOMO N/A
- ESPR N/A
- Industry
- DOMO Computer Software: Prepackaged Software
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- DOMO Technology
- ESPR Health Care
- Exchange
- DOMO Nasdaq
- ESPR Nasdaq
- Market Cap
- DOMO 324.2M
- ESPR 305.0M
- IPO Year
- DOMO 2018
- ESPR 2013
- Fundamental
- Price
- DOMO $6.40
- ESPR $1.21
- Analyst Decision
- DOMO Hold
- ESPR Buy
- Analyst Count
- DOMO 6
- ESPR 7
- Target Price
- DOMO $10.42
- ESPR $6.36
- AVG Volume (30 Days)
- DOMO 409.7K
- ESPR 4.6M
- Earning Date
- DOMO 05-22-2025
- ESPR 05-06-2025
- Dividend Yield
- DOMO N/A
- ESPR N/A
- EPS Growth
- DOMO N/A
- ESPR N/A
- EPS
- DOMO N/A
- ESPR N/A
- Revenue
- DOMO $317,044,000.00
- ESPR $332,314,000.00
- Revenue This Year
- DOMO $1.16
- ESPR $5.17
- Revenue Next Year
- DOMO $1.87
- ESPR N/A
- P/E Ratio
- DOMO N/A
- ESPR N/A
- Revenue Growth
- DOMO N/A
- ESPR 185.66
- 52 Week Low
- DOMO $6.11
- ESPR $1.28
- 52 Week High
- DOMO $10.15
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- DOMO 33.07
- ESPR 28.01
- Support Level
- DOMO $7.58
- ESPR $1.35
- Resistance Level
- DOMO $8.09
- ESPR $1.75
- Average True Range (ATR)
- DOMO 0.39
- ESPR 0.09
- MACD
- DOMO -0.17
- ESPR -0.03
- Stochastic Oscillator
- DOMO 1.68
- ESPR 4.81
About DOMO Domo Inc. Class B
Domo Inc provides a cloud-based platform that digitally connects all the data, systems and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.